Ginkgo Bioworks Holdings Inc(DNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 7:54 PM ET (Korea 10/29 08:54)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -5.44 | Insider Own | 23.67% | Shs Outstand | 52.3M | Perf Week | 33.07% |
| Market Cap | 0.90B | Forward P/E | - | EPS next Y | 13.94% | Insider Trans | -0.86% | Shs Float | 49.1M | Perf Month | 11.37% |
| Enterprise Value | 1.00B | PEG | - | EPS next Q | -0.68 | Inst Own | 58.61% | Short Float | 16.89% | Perf Quarter | 64.65% |
| Income | -0.32B | P/S | 8.02 | EPS this Y | 30.67% | Inst Trans | 8.55% | Short Ratio | 3.96 | Perf Half Y | 77.6% |
| Sales | 0.11B | P/B | 1.92 | EPS next 5Y | 29.22% | ROA | -26.55% | Short Interest | 8.29M | Perf YTD | 60.29% |
| Book/sh | 6.92 | P/C | 2.94 | EPS past 3/5Y | 51.73% -7.49% | ROE | -57.08% | 52W High | -26.89% ($18.22) | Perf Year | 4.55% |
| Cash/sh | 4.53 | P/FCF | - | Sales past 3/5Y | -29.11% 17.29% | ROIC | -38.25% | 52W Low | 148.04% ($5.37) | Perf 3Y | -75.33% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 7.05% | Gross Margin | 34.59% | Volatility(W/M) | 8.1% 13.05% | Perf 5Y | -97.67% |
| Dividend TTM | - | EV/Sales | 8.9 | Sales Y/Y TTM | -51.54% | Oper. Margin | -257.99% | ATR (14) | 1.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.57 | EPS Q/Q | -4.34% | Profit Margin | -281.87% | RSI (14) | 64.55 | Recom | 3.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.57 | Sales Q/Q | -59.37% | SMA20 | 16.12% ($11.47) | Beta | 1.74 | Target Price | $8 |
| Payout | - | Debt/Eq | 0.96 | Earnings | 2026/8/5 | SMA50 | 42.29% ($9.36) | Rel Volume | 1.79 | Prev Close | $11.27 |
| Employees | 485 | LT Debt/Eq | 0.96 | EPS/Sales Surpr. | 16.2% -16.19% | SMA200 | 55.56% ($8.56) | Avg Volume(3M) | 2.09M | Price | $13.32 |
| IPO | 2021/4/19 | Option/Short | Yes/Yes | Trades | 16141 | Volume | 3,756,496 | Change | 18.19% |
🧬 Ginkgo Bioworks (ticker: DNA) is a U.S. synthetic biology company that operates a cell engineering platform. It programs microorganisms and cells as if designing software, supporting customers across a range of industries—including pharmaceuticals, food, agriculture, and chemicals—in developing new materials through its automated foundry, and it also operates a separate biosecurity business.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
Traded more than usual. That is 179% of its average volume.
DNA has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +30.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $802. Peers typically go for $1,237. It is about in line with its own 3-year average.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Sell.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 58.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #171 of 594 in the industry
Based on market cap of $897M.
ANRO#169 Alto Neuroscience Inc $916M PER - 
OBX#170 Obsidian Therapeutics Inc $901M PER 0.1 DNA#171 Ginkgo Bioworks Holdings Inc $897M PER - 
CRVS#172 Corvus Pharmaceuticals Inc $886M PER - 
IVA#173 Inventiva ADR $885M PER - 
FAQ
What kind of company is DNA?
DNA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DNA?
The market cap of DNA is approximately $897M, ranking 2,677 within its sector.
What is the 52-week high and low for DNA?
DNA has recorded a 52-week high of $18.22 and a low of $5.37.
